|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Astra_Zeneca
|
|
gptkbp:awards
|
Best Startup
Innovative Company Award
Top 10 Biotech Companies
|
|
gptkbp:ceo
|
gptkb:David_A._Kessler
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
SYN-001 Phase 1
SYN-004 Phase 1
SYN-020 Phase 2
|
|
gptkbp:collaboration
|
academic institutions
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:MIT
|
|
gptkbp:focus
|
gptkb:immunotherapy
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:David_A._Kessler
|
|
gptkbp:goal
|
develop novel therapies
|
|
gptkbp:has_advisory_board
|
gptkb:Dr._Carl_June
gptkb:Dr._Anthony_Fauci
gptkb:Dr._Paul_Offit
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Syntimmune
|
|
gptkbp:instruction_set
|
SYN-001 for autoimmune diseases
SYN-004 for C. difficile
SYN-020 for cancer
|
|
gptkbp:investment
|
gptkb:New_Enterprise_Associates
gptkb:Sofinnova_Ventures
gptkb:Canaan_Partners
|
|
gptkbp:mission
|
transform patient care
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Roche
gptkb:Novartis
|
|
gptkbp:product
|
gptkb:SYN-004
gptkb:SYN-020
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:research_areas
|
gptkb:Oncology
autoimmune diseases
inflammatory diseases
|
|
gptkbp:research_focus
|
targeted therapies
immune modulation
Ig G antibodies
|
|
gptkbp:technology
|
monoclonal antibodies
biologics
|
|
gptkbp:vision
|
leading immunotherapy company
|
|
gptkbp:website
|
www.syntimmune.com
|
|
gptkbp:bfsParent
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|